Addressing the Next Generation of Therapies to Expand the Benefits Of TIL Across Multiple Indications

Time: 11:30 am
day: Day One


• Building on the successes of TIL therapies to drive towards commercialization

• Incorporating gene editing, discussing TIL and combination approaches to pursue effective next generation strategies

• Supporting development to ensure efficacy beyond melanoma to target lung cancer and other indications